Patents by Inventor Erik Meredith

Erik Meredith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10550102
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: February 4, 2020
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna, Nello Mainolfi, Mitsunori Kato
  • Publication number: 20190119254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 25, 2019
    Inventors: Christopher M. ADAMS, Doug BEVAN, Michael Paul CAPPARELLI, Takeru EHARA, Luciana FERRARA, Nan Ji, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA, Nello MAINOLFI, Mitsunori KATO
  • Patent number: 10208018
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 19, 2019
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Nello Mainolfi, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • Patent number: 9957254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: May 1, 2018
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Philippe Bolduc, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • Patent number: 9765067
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 19, 2017
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Takeru Ehara, Luciana Ferrara, Nan Ji, Donglei Liu, Erik Meredith, Muneto Mogi, James Powers, Ganesh Prasanna, Mitsunori Kato
  • Publication number: 20170197940
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, Doug BEVAN, Michael Paul CAPPARELLI, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Nello MAINOLFI, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • Publication number: 20170197950
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Takeru EHARA, Luciana FERRARA, Nan JI, Donglei LIU, Erik MEREDITH, Muneto MOGI, James POWERS, Ganesh PRASANNA, Mitsunori KATO
  • Publication number: 20170197941
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Philippe BOLDUC, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • Patent number: 9505755
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: November 29, 2016
    Assignee: NOVARTIS AG
    Inventors: Christopher Michael Adams, Veronique Darsigny, Alec Nathanson Flyer, Christine Fang Gelin, Timothy Brian Hurley, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Erik Meredith, Chang Rao, Michael H. Serrano-Wu, Catherine Fooks Solovay
  • Patent number: 9434754
    Abstract: The present invention relates to a method of treating a disease or disorder characterized by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4) alkyl, or —(C1-C4) alkyl-(C5-C7) aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4) alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10) aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: September 6, 2016
    Assignee: Novartis AG
    Inventors: Qi-Ying Hu, Gary Michael Ksander, Erik Meredith, Lauren G Monovich, Julien Papillon, Christoph Schumacher
  • Patent number: 9278969
    Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: March 8, 2016
    Assignee: Novartis AG
    Inventors: Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu
  • Publication number: 20140357621
    Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu
  • Publication number: 20140349995
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Christopher Michael ADAMS, Veronique DARSIGNY, Alec Nathanson FLYER, Christine Fang GELIN, Timothy Brian HURLEY, Nan JI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Erik MEREDITH, Chang RAO, Michael H. SERRANO-WU, Catherine Fooks SOLOVAY
  • Patent number: 8846656
    Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 30, 2014
    Assignee: Novartis AG
    Inventors: Christopher Michael Adams, Veronique Darsigny, Alec Nathanson Flyer, Christine Fang Gelin, Timothy Brian Hurley, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Erik Meredith, Chang Rao, Michael H. Serrano-Wu, Catherine Fooks Solovay
  • Patent number: 8835646
    Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: September 16, 2014
    Assignee: Novartis AG
    Inventors: Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu
  • Publication number: 20140171392
    Abstract: The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4) alkyl, or —(C1-C4) alkyl-(C5-C7) aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4) alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10) aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 13, 2013
    Publication date: June 19, 2014
    Applicant: Novartis AG
    Inventors: Qi-Ying Hu, Gary Michael Ksander, Erik Meredith, Lauren G. Monovich, Julien Papillon, Christoph Schumacher
  • Patent number: 8609862
    Abstract: The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4)alkyl, or —(C1-C4)alkyl-(C5-C7)aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4)alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10)aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: December 17, 2013
    Assignee: Novartis AG
    Inventors: Qi-Ying Hu, Gary Michael Ksander, Erik Meredith, Lauren G. Monovich, Julien Papillon, Christoph Schumacher
  • Publication number: 20130287789
    Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.
    Type: Application
    Filed: June 26, 2013
    Publication date: October 31, 2013
    Applicant: Novartis AG
    Inventors: Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu
  • Patent number: 8541432
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 24, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Patent number: 8501756
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 6, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao